Trials / Completed
CompletedNCT04243304
Synaptic Density and Progression of Parkinson's Disease.
Longitudinal Measurement of Synaptic Density to Monitor Progression of Parkinson's Disease.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with PD. DESIGN: We will include 30 PD patients and 20 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FE-PE2I PET-MR at baseline and after 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 11C-UCB-J PET-CT | Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J. |
| OTHER | 18F-PE2I PET-MR | Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously. |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2020-01-28
- Last updated
- 2022-05-19
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04243304. Inclusion in this directory is not an endorsement.